Shareholder Derivative

     PHILADELPHIA – Hemispherix Biopharma handed out big bonuses to its top dogs despite their misrepresentation of trials of its Ampligen drug, which ended so badly it knocked 43% off the share price in one day, shareholders say in a derivative complaint in state court.

%d bloggers like this: